메뉴 건너뛰기




Volumn 119, Issue 18, 2013, Pages 3334-3342

Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma

Author keywords

chemotherapy; downsizing; hepatocellular carcinoma; liver resection; PIAF; response; survival; tolerance

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; DOXORUBICIN; FLUOROURACIL;

EID: 84883598201     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28209     Document Type: Article
Times cited : (31)

References (39)
  • 1
    • 0033646209 scopus 로고    scopus 로고
    • Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan
    • Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000; 32: 1224-1229.
    • (2000) Hepatology , vol.32 , pp. 1224-1229
    • Arii, S.1    Yamaoka, Y.2    Futagawa, S.3
  • 3
    • 38649141497 scopus 로고    scopus 로고
    • Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?
    • DOI 10.1002/hep.21933
    • Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008; 47: 82-89. (Pubitemid 351171044)
    • (2008) Hepatology , vol.47 , Issue.1 , pp. 82-89
    • Livraghi, T.1    Meloni, F.2    Di Stasi, M.3    Rolle, E.4    Solbiati, L.5    Tinelli, C.6    Rossi, S.7
  • 4
    • 84859586321 scopus 로고    scopus 로고
    • Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors
    • Shiina S, Tateishi R, Arano T, et al. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012; 107: 569-577.
    • (2012) Am J Gastroenterol , vol.107 , pp. 569-577
    • Shiina, S.1    Tateishi, R.2    Arano, T.3
  • 5
    • 84855314307 scopus 로고    scopus 로고
    • Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report
    • Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A,. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012; 13: e11-e22.
    • (2012) Lancet Oncol , vol.13
    • Clavien, P.A.1    Lesurtel, M.2    Bossuyt, P.M.3    Gores, G.J.4    Langer, B.5    Perrier, A.6
  • 6
    • 4344652107 scopus 로고    scopus 로고
    • Living donor liver transplantation for adult patients with hepatocellular carcinoma: Experience in Japan
    • Todo S, Furukawa H,. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004; 240: 451-459.
    • (2004) Ann Surg , vol.240 , pp. 451-459
    • Todo, S.1    Furukawa, H.2
  • 7
    • 0031048958 scopus 로고    scopus 로고
    • Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
    • DOI 10.1023/A:1008285123736
    • Simonetti RG, Liberati A, Angiolini C, Pagliaro L,. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997; 8: 117-136. (Pubitemid 27112878)
    • (1997) Annals of Oncology , vol.8 , Issue.2 , pp. 117-136
    • Simonetti, R.G.1    Liberati, A.2    Angiolini, C.3    Pagliaro, L.4
  • 10
    • 0037080414 scopus 로고    scopus 로고
    • Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy
    • DOI 10.1002/cncr.10236
    • Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002; 94: 421-427. (Pubitemid 34081372)
    • (2002) Cancer , vol.94 , Issue.2 , pp. 421-427
    • Leung, T.W.T.1    Tang, A.M.Y.2    Zee, B.3    Yu, S.C.H.4    Lai, P.B.S.5    Lau, W.Y.6    Johnson, P.J.7
  • 13
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 16
    • 0024581695 scopus 로고
    • Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection
    • Lai KH, Tsai YT, Lee SD, et al. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol. 1989; 23: 54-56.
    • (1989) Cancer Chemother Pharmacol , vol.23 , pp. 54-56
    • Lai, K.H.1    Tsai, Y.T.2    Lee, S.D.3
  • 18
    • 1642613800 scopus 로고
    • Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma
    • Zaniboni A, Simoncini E, Marpicati P, Marini G,. Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma. Br J Cancer. 1988; 57: 319. (Pubitemid 18096346)
    • (1988) British Journal of Cancer , vol.57 , Issue.3 , pp. 319
    • Zaniboni, A.1    Simoncini, E.2    Marpicati, P.3    Marini, G.4
  • 19
    • 47949116252 scopus 로고    scopus 로고
    • Sorafenib in advanced hepatocellular carcinoma
    • Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
    • (2008) N Engl J Med , vol.359 , pp. 378-390
    • Llovet, J.M.1    Ricci, S.2    Mazzaferro, V.3
  • 20
    • 57749189578 scopus 로고    scopus 로고
    • Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial
    • Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
    • (2009) Lancet Oncol , vol.10 , pp. 25-34
    • Cheng, A.L.1    Kang, Y.K.2    Chen, Z.3
  • 21
    • 0035134510 scopus 로고    scopus 로고
    • Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma
    • DOI 10.1097/00000658-200102000-00013
    • Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg. 2001; 233: 236-241. (Pubitemid 32106078)
    • (2001) Annals of Surgery , vol.233 , Issue.2 , pp. 236-241
    • Lau, W.-Y.1    Leung, T.W.T.2    Lai, B.-S.3    Liew, C.-T.4    Ho, S.K.W.5    Yu, S.C.H.6    Tang, A.M.Y.7
  • 22
    • 0037129704 scopus 로고    scopus 로고
    • Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial
    • DOI 10.1016/S0140-6736(02)08649-X
    • Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359: 1734-1739. (Pubitemid 34607087)
    • (2002) Lancet , vol.359 , Issue.9319 , pp. 1734-1739
    • Llovet, J.M.1    Real, M.I.2    Montana, X.3    Planas, R.4    Coll, S.5    Aponte, J.6    Ayuso, C.7    Sala, M.8    Muchart, J.9    Sola, R.10    Rodes, J.11    Bruix, J.12
  • 23
    • 0036237822 scopus 로고    scopus 로고
    • Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma
    • DOI 10.1053/jhep.2002.33156
    • Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35: 1164-1171. (Pubitemid 34454013)
    • (2002) Hepatology , vol.35 , Issue.5 , pp. 1164-1171
    • Lo, C.-M.1    Ngan, H.2    Tso, W.-K.3    Liu, C.-L.4    Lam, C.-M.5    Poon, R.T.-P.6    Fan, S.-T.7    Wong, J.8
  • 24
    • 80053974116 scopus 로고    scopus 로고
    • Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma
    • Kaseb AO, Morris JS, Hassan MM, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011; 29: 3892-3899.
    • (2011) J Clin Oncol , vol.29 , pp. 3892-3899
    • Kaseb, A.O.1    Morris, J.S.2    Hassan, M.M.3
  • 25
    • 77955973284 scopus 로고    scopus 로고
    • Advanced hepatocellular carcinoma: Which staging systems best predict prognosis?
    • Huitzil-Melendez FD, Capanu M, O'Reilly EM, et al. Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol. 2010; 28: 2889-2895.
    • (2010) J Clin Oncol , vol.28 , pp. 2889-2895
    • Huitzil-Melendez, F.D.1    Capanu, M.2    O'Reilly, E.M.3
  • 26
    • 0031782818 scopus 로고    scopus 로고
    • A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
    • Cancer of the Liver Italian Program (CLIP) investigators
    • Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998; 28: 751-755.
    • (1998) Hepatology , vol.28 , pp. 751-755
  • 27
    • 0032879468 scopus 로고    scopus 로고
    • Prognosis of hepatocellular carcinoma: The BCLC staging classification
    • Llovet JM, Bru C, Bruix J,. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
    • (1999) Semin Liver Dis , vol.19 , pp. 329-338
    • Llovet, J.M.1    Bru, C.2    Bruix, J.3
  • 28
    • 0021965806 scopus 로고
    • Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients
    • DOI 10.1002/1097-0142(19850815)56:4 <918::AID-CNCR2820560437>3.0. CO;2-E
    • Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56: 918-928. (Pubitemid 15228292)
    • (1985) Cancer , vol.56 , Issue.4 , pp. 918-928
    • Okuda, K.1    Ohtsuki, T.2    Obata, H.3
  • 29
    • 0037086560 scopus 로고    scopus 로고
    • Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients
    • DOI 10.1002/cncr.10384
    • Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002; 94: 1760-1769. (Pubitemid 34241115)
    • (2002) Cancer , vol.94 , Issue.6 , pp. 1760-1769
    • Leung, T.W.T.1    Tang, A.M.Y.2    Zee, B.3    Lau, W.Y.4    Lai, P.B.S.5    Leung, K.L.6    Lau, J.T.F.7    Yu, S.C.H.8    Johnson, P.J.9
  • 30
    • 0346896573 scopus 로고    scopus 로고
    • AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: Consensus statement
    • DOI 10.1080/13651820310015833
    • Henderson JM, Sherman M, Tavill A, Abecassis M, Chejfec G, Gramlich T,. AHPBA/AJCC consensus conference on staging of hepatocellular carcinoma: consensus statement. HPB (Oxford). 2003; 5: 243-250. (Pubitemid 38008080)
    • (2003) HPB , vol.5 , Issue.4 , pp. 243-250
    • Henderson, J.M.1    Sherman, M.2    Tavill, A.3    Abecassis, M.4    Chejfec, G.5    Gramlich, T.6
  • 31
    • 7044231396 scopus 로고    scopus 로고
    • Hepatocellular carcinoma: Recent trends in the United States
    • DOI 10.1053/j.gastro.2004.09.013, PII S0016508504015926
    • El-Serag HB,. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004; 127: S27-S34. (Pubitemid 39423367)
    • (2004) Gastroenterology , vol.127 , Issue.SUPPL.
    • El-Serag, H.B.1
  • 32
    • 79953185045 scopus 로고    scopus 로고
    • Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis
    • Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011; 128: 2436-2443.
    • (2011) Int J Cancer , vol.128 , pp. 2436-2443
    • Ertle, J.1    Dechene, A.2    Sowa, J.P.3
  • 33
    • 55549106451 scopus 로고    scopus 로고
    • Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?
    • Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ,. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med. 2008; 132: 1761-1766.
    • (2008) Arch Pathol Lab Med , vol.132 , pp. 1761-1766
    • Guzman, G.1    Brunt, E.M.2    Petrovic, L.M.3    Chejfec, G.4    Layden, T.J.5    Cotler, S.J.6
  • 34
    • 84055193440 scopus 로고    scopus 로고
    • Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?
    • Hashimoto E, Tokushige K,. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012; 42: 1-14.
    • (2012) Hepatol Res , vol.42 , pp. 1-14
    • Hashimoto, E.1    Tokushige, K.2
  • 35
    • 84863340542 scopus 로고    scopus 로고
    • Recent trend of clinical features in patients with hepatocellular carcinoma
    • Nagaoki Y, Hyogo H, Aikata H, et al. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012; 42: 368-375.
    • (2012) Hepatol Res , vol.42 , pp. 368-375
    • Nagaoki, Y.1    Hyogo, H.2    Aikata, H.3
  • 36
    • 63349085247 scopus 로고    scopus 로고
    • Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis
    • Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009; 49: 851-859.
    • (2009) Hepatology , vol.49 , pp. 851-859
    • Paradis, V.1    Zalinski, S.2    Chelbi, E.3
  • 38
    • 73149120271 scopus 로고    scopus 로고
    • Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
    • Siegel AB, Zhu AX,. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009; 115: 5651-5661.
    • (2009) Cancer , vol.115 , pp. 5651-5661
    • Siegel, A.B.1    Zhu, A.X.2
  • 39
    • 79960747094 scopus 로고    scopus 로고
    • Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database
    • Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA,. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54: 463-471.
    • (2011) Hepatology , vol.54 , pp. 463-471
    • Welzel, T.M.1    Graubard, B.I.2    Zeuzem, S.3    El-Serag, H.B.4    Davila, J.A.5    McGlynn, K.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.